Ticker >

Genpharmasec share price

Genpharmasec Ltd.

BSE: 531592 SECTOR: Dyes & Pigments  32k   153   19

2.45
0 0
BSE: 12 Apr 04:01 PM

Price Summary

Today's High

₹ 2.45

Today's Low

₹ 2.45

52 Week High

₹ 7.31

52 Week Low

₹ 1.69

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

135.66 Cr.

Enterprise Value

136.75 Cr.

No. of Shares

55.37 Cr.

P/E

118.93

P/B

2.12

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  1.15

CASH

1.99 Cr.

DEBT

3.08 Cr.

Promoter Holding

29.98 %

EPS (TTM)

₹  0.02

Sales Growth

-6.61%

ROE

7.33 %

ROCE

2%

Profit Growth

637.15 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-6.61%
3 Year15.64%
5 Year215.59%

Profit Growth

1 Year637.15%
3 Year3.67%
5 Year88.17%

ROE%

1 Year7.33%
3 Year4.58%
5 Year4.3%

ROCE %

1 Year2%
3 Year2.38%
5 Year3.14%

Debt/Equity

0.201

Price to Cash Flow

-41.94

Interest Cover Ratio

6.02857142857143

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 29.98 0
Dec 2023 59.96 0
Sep 2023 59.96 0
Jun 2023 59.96 0
Mar 2023 59.96 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 15.6367229171273% for the Past 3 years.
  • Company’s PEG ratio is 0.187527696088305.
  • Company has a healthy liquidity position with current ratio of 9.1724572370015.

 Limitations

  • The company has shown a poor profit growth of 3.67487222142924% for the Past 3 years.
  • Company has a poor ROE of 4.58132879151586% over the past 3 years.
  • Company has a poor ROCE of 2.38146762309762% over the past 3 years
  • Company has negative cash flow from operations of -3.2344.
  • The company has a low EBITDA margin of -2.92277376142917% over the past 5 years.
  • The company is trading at a high PE of 118.93.
  • The company is trading at a high EV/EBITDA of 203.3622.
  • Promoter stake has been decreased from 59.96% to 29.98%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 6.41 6.22 5.96 7.86 6.39
Total Expenditure 6.18 6.01 5.94 7.9 6.37
Operating Profit 0.22 0.21 0.02 -0.04 0.02
Other Income 0.02 0.06 0.11 0.15 0.14
Interest 0 0.06 0.06 0.07 0.13
Depreciation 0.01 0.01 0.01 0 0.01
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.24 0.2 0.06 0.05 0.03
Tax 0 -0.84 0.04 0.04 -0.03
Profit After Tax 0.24 1.05 0.03 0.01 0.06
Adjusted EPS (Rs) 0.01 0.02 0 0 0

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 0.38 16.5 21.31 27.32 25.52
Total Expenditure 0.46 15.85 20.11 27.84 25.26
Operating Profit -0.09 0.65 1.19 -0.52 0.26
Other Income 0.37 0.56 0.33 0.09 0.1
Interest 0 0 0 0 0.06
Depreciation 0 0 0.01 0.01 0.02
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.29 1.21 1.51 -0.44 0.28
Tax 0.06 0.2 0.25 -0.23 -0.84
Net Profit 0.23 1.01 1.26 -0.21 1.12
Adjusted EPS (Rs.) 0.01 0.03 0.03 0 0.02

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 21.69 21.69 21.69 27.69 27.69
Total Reserves -0.07 -2.65 -1.02 -12.32 -12.36
Borrowings 0 0 0 0 2.48
Other N/C liabilities 0 0 0 0 -0.85
Current liabilities 0.02 5.72 7.16 6.28 2.06
Total Liabilities 21.63 24.75 27.82 21.65 19.03
Assets
Net Block 0 0.05 0.05 0.1 0.1
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 6.05 3.48 0.14 0 0
Loans & Advances 2.65 5.34 0.85 0 0
Other N/C Assets 5.25 0 0 0 0
Current Assets 7.68 15.88 26.78 21.54 18.93
Total Assets 21.63 24.75 27.82 21.65 19.03
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 0.29 1.21 1.51 -0.44 0.28
Adjustment -0.37 -0.54 -0.31 -0.04 -0.01
Changes in Assets & Liabilities -6.25 0.78 -2.98 -1.83 -3.77
Tax Paid -0.07 -0.05 -0.35 -0.03 0.26
Operating Cash Flow -6.4 1.39 -2.13 -2.34 -3.23
Investing Cash Flow -10.42 -4.01 -1.41 0.42 0.54
Financing Cash Flow 21.87 0 4.5 0 3.08
Net Cash Flow 5.04 -2.62 0.96 -1.93 0.39

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 59.96 59.96 59.96 59.96 29.98
rajesh sadhwani 26.37 26.37 26.37 26.37 13.18
sneha sadhwani 33.59 33.59 33.59 33.59 16.80
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 40.04 40.04 40.04 40.04 70.02
divya deven pathak - - - - 1.99
mansi share & stock advis... - - - - 2.71
multiplier share & stock ... - - - - 2.40
narendra chhaganlal solan... - - - - 1.09
ramesh sakharampant deshp... - - - - 1.08
rashmi nimesh joshi - 1.00 1.28 1.28 1.28
sadashiv kanyana shetty - - - - 1.80
vishesh mahesh nihalani - - - - 1.52
yogeshkumar rasiklal sang... - - - - 7.82
jigney bhachech huf 1.22 1.44 1.44 1.44 -
manish ravilal patel huf 1.75 1.30 1.09 1.09 -
dinesh ravilal patel huf 1.73 1.28 1.03 - -
mitul ravilal patel huf 2.17 1.72 1.42 - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Genpharmasec informs about board meeting 21 Mar 2024, 4:48PM Genpharmasec acquires 70% stake in Derren Healthcare11 Mar 2024, 5:52PM Genpharmasec informs about updates on acquisition 11 Mar 2024, 4:27PM Genpharmasec - Quaterly Results12 Feb 2024, 5:02PM Genpharmasec - Quaterly Results12 Feb 2024, 5:02PM Genpharmasec - Quaterly Results12 Feb 2024, 5:02PM Genpharmasec forms wholly owned subsidiary 29 Jan 2024, 4:47PM Genpharmasec informs about newspaper advertisement22 Jan 2024, 4:54PM Genpharmasec informs about outcome of board meeting 11 Dec 2023, 3:37PM Genpharmasec informs about board meeting 1 Nov 2023, 5:13PM Genpharmasec to acquire 70% stake in Derren Healthcare20 Sep 2023, 2:42PM Genpharmasec informs about AGM1 Sep 2023, 12:43PM Genpharmasec incorporates foreign subsidiary14 Jul 2023, 2:28PM Genpharmasec informs about incorporation of subsidiary company14 Jul 2023, 2:16PM Genpharmasec planning to raise funds 30 May 2023, 3:40PM Genpharmasec informs about newspaper publication10 May 2023, 5:39PM Genpharmasec informs about compliance certificate18 Apr 2023, 5:16PM Genpharmasec informs about separate meeting of independent directors27 Mar 2023, 4:53PM Genpharmasec - Quaterly Results10 Feb 2023, 5:37PM Genpharmasec - Quaterly Results10 Feb 2023, 5:37PM Genpharmasec informs about financial results14 Nov 2022, 5:44PM Genpharmasec informs about resignation of director11 Oct 2022, 4:25PM Genpharmasec informs about resignation of independent director6 Oct 2022, 4:21PM Genpharmasec informs about scrutinizers report3 Oct 2022, 5:00PM Genpharmasec informs about annual report6 Sep 2022, 12:55PM Genpharmasec - Quaterly Results10 Aug 2022, 4:31PM Genpharmasec informs about board meeting18 May 2022, 3:21PM Genpharmasec - Quaterly Results14 Feb 2022, 6:07PM Genpharmasec informs about disclosure19 Jan 2022, 10:01AM Generic Pharmasec informs about confirmation certificate14 Oct 2021, 3:13PM Generic Pharmasec successfully executes order from Reliance Group27 Jul 2021, 12:48PM Generic Pharmasec enters into agreement with Abbott Point of Care1 Jun 2021, 12:00PM Generic Pharmasec submits compliance certificate20 Apr 2021, 5:16PM Generic Pharmasec informs about board meeting2 Feb 2021, 4:04PM

Genpharmasec Stock Price Analysis and Quick Research Report. Is Genpharmasec an attractive stock to invest in?

 

Stock investing requires careful analysis of financial data to find out the company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement. This can be time-consuming and cumbersome. An easier way to find out about a company's performance is to look at its financial ratios, which can help to make sense of the overwhelming amount of information that can be found in a company's financial statements.

Here are the few indispensable tools that should be a part of every investor’s research process.

  • PE ratio: - Price to Earnings' ratio, which indicates for every rupee of earnings how much an investor is willing to pay for a share. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Genpharmasec has a PE ratio of 118.932038834951 which is high and comparatively overvalued .

  • Share Price: - The current share price of Genpharmasec is Rs 2.45. One can use valuation calculators of ticker to know if Genpharmasec share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Genpharmasec has ROA of 5.53045239769302 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Genpharmasec has a Current ratio of 9.1724572370015 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Genpharmasec has a ROE of 7.32771116518295 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Genpharmasec has a D/E ratio of 0.201 which means that the company has low proportion of debt in its capital.

  • Inventory turnover ratio: - Inventory Turnover ratio is an activity ratio and is a tool to evaluate the liquidity of a company's inventory. It measures how many times a company has sold and replaced its inventory during a certain period of time. Genpharmasec has an Inventory turnover ratio of 2.60838052789761 which shows that the management is inefficient in relation to its Inventory and working capital management.

  • Sales growth: - Genpharmasec has reported revenue growth of -6.60602844018227 % which is poor in relation to its growth and performance.

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Genpharmasec for the current financial year is 1.00800683500748 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Genpharmasec is Rs 0 and the yield is 0 %.

Last Updated on:
Brief about Genpharmasec
X